Micropharma Limited announces new agreement to commercialize novel natural health products
MONTREAL, Aug. 13, 2013 /PRNewswire-iReach/ -- Micropharma Limited, a pioneer in the development of health products based on the human microbiome, today announced that they have reached an agreement with Atrium Innovations Inc., a world leader in science-based natural health products, to commercialize products to be sold directly to healthcare practitioners. For Micropharma, this agreement provides access to commercialize its technologies in new key markets.
Atrium owns healthcare practitioner and specialized retail product brands that are at the forefront of science, innovation and education and distributes these products in more than 35 countries. Micropharma Limited sees a large and growing gap between lifestyle management and prescription drug treatment options for chronic and metabolic conditions coupled with consumer demand for more natural solutions. CEO of Micropharma Ryan Jones said "The market for highly innovative health products is large and growing. With Atrium's strong track record of success in launching these types of products coupled with its solid presence in the healthcare practitioner market, we are optimistic about the potential of the agreement which will allow us to further develop new microbiome-developed and proven technologies with a clear channel to get these effective products to those who need them."
Both Micropharma and Atrium Innovations are Quebec, Canada companies.
About Micropharma Limited
Micropharma is a Canadian biotechnology company focused on human health through the microbiome. The company applies a unique approach, ProSelect, to the discovery and commercialization of novel products based on the human microbiome for the diagnosis and treatment of metabolic diseases. Micropharma works on disease specific products with clear microbiome related mechanisms, and links to biomarkers that are associated with improving human health. Micropharma is developing diagnostics and oral biologic therapies in the area of metabolic disease including hypercholesterolemia, metabolic syndrome, obesity, and diabetes. For more info go to www.micropharma.net
Media Contact: Christopher Wahl, Micropharma Limited, 514-524-2828, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Micropharma Limited